Black Diamond Therapeutics, Inc.

The NASDAQ 100 Pre-Market Indicator is up 63.08 to 19,546.44. The total Pre-Market volume is currently 85,515,132 shares traded.
The following are the most active stocks for the pre-market session:
Black Diamond Therapeutics, Inc. (BDTX) is +0.75 at $2.43, with 17,874,342 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2025. The consensus EPS forecast is $-0.25. As reported in the last short interest update the days to cover for BDTX is 17.550886; this calculation is based on the average trading volume of the stock.
Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.4 at $7.87, with 14,687,409 shares traded. This represents a 59.31% increase from its 52 Week Low.
iShares Short Treasury Bond ETF (SHV) is +0.02 at $110.32, with 5,662,391 shares traded. This represents a .37% increase from its 52 Week Low.
NVIDIA Corporation (NVDA) is +1.14 at $116.57, with 4,800,670 shares traded. Over the last four weeks they have had 8 up revisions for the earnings forecast, for the fiscal quarter ending Apr 2025. The consensus EPS forecast is $0.87. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
Tesla, Inc. (TSLA) is +6.29 at $231.60, with 3,282,264 shares traded. TSLA's current last sale is 61.51% of the target price of $376.5.
Intel Corporation (INTC) is -0.68 at $25.24, with 2,434,610 shares traded. INTC's current last sale is 109.74% of the target price of $23.
D-Wave Quantum Inc. (QBTS) is -0.06 at $10.74, with 1,528,244 shares traded. As reported by Zacks, the current mean recommendation for QBTS is in the "buy range".
NIO Inc. (NIO) is +0.07 at $5.26, with 1,420,528 shares traded.NIO is scheduled to provide an earnings report on 3/21/2025, for the fiscal quarter ending Dec2024. The consensus earnings per share forecast is -0.42 per share, which represents a -45 percent increase over the EPS one Year Ago
BigBear.ai, Inc. (BBAI) is +0.0499 at $3.02, with 761,662 shares traded. BBAI's current last sale is 50.33% of the target price of $6.
Alibaba Group Holding Limited (BABA) is +3.45 at $146.19, with 695,359 shares traded. BABA's current last sale is 98.44% of the target price of $148.5.
IonQ, Inc. (IONQ) is +0.46 at $23.14, with 603,255 shares traded. As reported by Zacks, the current mean recommendation for IONQ is in the "buy range".
Pfizer, Inc. (PFE) is +0.0299 at $26.34, with 483,258 shares traded. PFE's current last sale is 87.8% of the target price of $30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Mar 19, 2025 : BDTX, TSLL, SHV, NVDA, TSLA, INTC, QBTS, NIO, BBAI, BABA, IONQ, PFE

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Morgan Stanley Pathway Small-Mid Cap Equity ETF (Symbol: MSSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $57.85 per unit.
With MSSM trading at a recent price near $48.45 per unit, that means that analysts see 19.41% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of MSSM's underlying holdings with notable upside to their analyst target prices are Adverum Biotechnologies Inc (Symbol: ADVM), Black Diamond Therapeutics Inc (Symbol: BDTX), and Getty Images Holdings Inc (Symbol: GETY). Although ADVM has traded at a recent price of $4.00/share, the average analyst target is 642.85% higher at $29.71/share. Similarly, BDTX has 511.81% upside from the recent share price of $2.37 if the average analyst target price of $14.50/share is reached, and analysts on average are expecting GETY to reach a target price of $5.61/share, which is 130.00% above the recent price of $2.44. Below is a twelve month price history chart comparing the stock performance of ADVM, BDTX, and GETY:
Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
Morgan Stanley Pathway Small-Mid Cap Equity ETF
MSSM
$48.45
$57.85
19.41%
Adverum Biotechnologies Inc
ADVM
$4.00
$29.71
642.85%
Black Diamond Therapeutics Inc
BDTX
$2.37
$14.50
511.81%
Getty Images Holdings Inc
GETY
$2.44
$5.61
130.00%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
Also see:
Rithm Property Earnings History
MCEP Insider Buying
Top Ten Hedge Funds Holding AFGD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

MSSM's Underlying Holdings Imply 19% Gain Potential

Health care stocks were edging higher pre-bell Monday as the Health Care Select Sector SPDR Fund (XLV) advanced by 0.1% and the iShares Biotechnology ETF (IBB) was up 0.5% recently.
Black Diamond Therapeutics (BDTX) shares rose past 16% after the company said initial phase 2 data of its BDTX-1535 experimental therapy to treat a type of non-small cell lung cancer demonstrated "robust anti-tumor activity."
Biohaven (BHVN) shares were up over 13% after the company said its pivotal study of troriluzole in spinocerebellar ataxia, a progressive brain disorder, achieved its primary endpoint of a change from baseline in a measure of disease progression at 3 years in all groups.
Ideaya Biosciences (IDYA) shares advanced by nearly 8% after the company said a phase 2 trial evaluating investigational drug darovasertib for treating neoadjuvant uveal melanoma showed interim results that were "clinically meaningful."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.